Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC.ATOS · Entity 7556 | Director · President & CEO | March 27, 2026 | March 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATOSSA THERAPEUTICS, INC.
Report date March 27, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,038 |
Reported balance
After 2026-03-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-27 · Grant · Acquired 65,000 · Balance 88,038 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments on the first three anniversaries of March 26, 2026. F2: On February 2, 2026, the Issuer effected a one-for-fifteen reverse stock split of its Common Stock (the "Reverse Stock Split"). The number of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. |
| Common StockSEC Table I · non-derivative | IndirectBy Ensisheim Partners, LLC | 1,483 |
Reported balance
Holding disclosure · report date 2026-03-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,483 F2: On February 2, 2026, the Issuer effected a one-for-fifteen reverse stock split of its Common Stock (the "Reverse Stock Split"). The number of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. F3: Ensisheim Partners, LLC ("Ensisheim") is wholly owned by the Reporting Person and Dr. Shu-Chih Chen. The Reporting Person and Dr. Chen share voting and investment power over the securities held by Ensisheim. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments on the first three anniversaries of March 26, 2026.
F2: On February 2, 2026, the Issuer effected a one-for-fifteen reverse stock split of its Common Stock (the "Reverse Stock Split"). The number of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.
F3: Ensisheim Partners, LLC ("Ensisheim") is wholly owned by the Reporting Person and Dr. Shu-Chih Chen. The Reporting Person and Dr. Chen share voting and investment power over the securities held by Ensisheim. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2026 Filed Mar 31, 2026 16:57 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-134861 · ownership.xml · nonDerivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,038 F1 · shares: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments on the first three anniversaries of March 26, 2026. F2 · balance_after: On February 2, 2026, the Issuer effected a one-for-fifteen reverse stock split of its Common Stock (the "Reverse Stock Split"). The number of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 14:11 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Options (right to buy) · Derivative | 950,000 | $0.60 Strike: $0.60 | $572,850.00 |
DisclosureSEC source: 0001193125-26-019273 · ownership.xml · derivative · entry 3 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 950,000 Underlying: Common Stock · 950,000 shares Expires 2026-01-20 F3 · derivative.exercise_date: The options shall vest on a quarterly basis over 24 months following January 20, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on January 20, 2026, with an exercise price of $0.603, representing the closing stock price on January 20, 2026. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 14:11 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantCommon Stock | 325,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-019273 · ownership.xml · nonDerivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,101 F1 · security: Represents the acquisition of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest one year from the Transaction date. Read SEC document |
| January 20, 2026 Filed Jan 30, 2026 08:30 UTC Amendment | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Options (right to buy) · Derivative | 950,000 | $0.60 Strike: $0.60 | $572,850.00 |
DisclosureSEC source: 0001193125-26-030571 · ownership.xml · derivative · entry 3 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 950,000 Underlying: Common Stock · 950,000 shares Expires 2026-01-20 F4 · derivative.exercise_date: The options shall vest on a quarterly basis over 24 months following January 20, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on January 20, 2026, with an exercise price of $0.603, representing the closing stock price on January 20, 2026. Read SEC document |
| January 20, 2026 Filed Jan 30, 2026 08:30 UTC Amendment | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantCommon Stock | 331,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-030571 · ownership.xml · nonDerivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,572 F1 · security: Represents the acquisition of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest one year from the Transaction Date. F2 · shares: The original Form 4, filed on January 22, 2026, is being amended by this Form 4 amendment solely to correct an administrative error regarding the number of RSUs acquired. Read SEC document |
| May 21, 2025 Filed May 22, 2025 18:27 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | PurchaseCommon Stock | 11,239 | $0.88 | $9,886.95 |
DisclosureSEC source: 0000950170-25-076523 · ownership.xml · nonDerivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,898 F1 · price: The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $0.8794 to $0.9100. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of share purchased at each separate price. Read SEC document |
| May 15, 2025 Filed May 16, 2025 16:05 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 1,366,062 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0000950170-25-073520 · ownership.xml · derivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,366,062 Underlying: Common Stock · 1,366,062 shares Expires 2035-05-15 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over 24 months following May 15, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on May 15, 2025, with an exercise price of $0.99, representing the closing stock price on May 15, 2025. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 16:00 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 1,795,100 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0000950170-24-079559 · ownership.xml · derivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,795,100 Underlying: Common Stock · 1,795,100 shares Expires 2034-06-27 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over 24 months following June 27, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued at approximately 9:30 a.m. (ET) on June 27, 2024, with an exercise price of $1.05, representing the most recently reported closing stock price on June 26, 2024. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 16:11 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 1,873,100 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001437749-23-005533 · rdgdoc.xml · derivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,873,100 Underlying: Common Stock · 1,873,100 shares Expires 2033-03-02 F1 · derivative.exercise_date: The option will vest and become exercisable on a quarterly basis over 24 months from the grant-date. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 17:15 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 1,900,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001437749-22-004667 · rdgdoc.xml · derivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900,000 Underlying: Common Stock · 1,900,000 shares Expires 2032-02-24 F1 · derivative.exercise_date: The options will vest on a quarterly basis over two (2) years. Read SEC document |
| May 14, 2021 Filed May 18, 2021 16:18 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 1,900,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001437749-21-012674 · rdgdoc.xml · derivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900,000 Underlying: Common Stock · 1,900,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: The options will vest on a quarterly basis over the next 24 months. Option grant was issued at 4:30 p.m. (ET) on May 14, 2021 with an exercise price of $2.90, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| May 14, 2021 Filed May 18, 2021 16:18 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 1,900,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001437749-21-012676 · rdgdoc.xml · derivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900,000 Underlying: Common Stock · 1,900,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: The options will vest on a quarterly basis over the next 24 months. Option grant was issued at 4:30 p.m. (ET) on May 14, 2021 with an exercise price of $2.90, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 18:20 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (Right to Buy) · Derivative | 1,305,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001437749-20-007628 · rdgdoc.xml · derivative · entry 2 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,305,000 Underlying: Common Shares · 1,305,000 shares Expires 2030-04-09 F2 · derivative.exercise_date: The options will vest quarterly in equal amounts over two years from the grant date (April 9, 2020), subject to continued employment with the Company through the applicable vesting dates. However, 50% of all then-unvested options will vest immediately upon the achievement of certain milestones. The stock options are also subject to stockholder approval of the 2020 Stock Incentive Plan of the Company, which approval must occur within one year from the grant date. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 18:20 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001437749-20-007628 · rdgdoc.xml · derivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Shares · 195,000 shares Expires 2030-04-09 F1 · derivative.exercise_date: The options will vest quarterly in equal amounts over two years from the grant date (April 9, 2020), subject to continued employment with the Company through the applicable vesting dates. Read SEC document |
| January 13, 2019 Filed Jan 15, 2019 16:10 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (Right to Buy) · Derivative | 2,300,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001615774-19-000645 · s115379_form4.xml · derivative · entry 2 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300,000 Underlying: Common Shares · 2,300,000 shares Expires 2029-01-13 F1 · kind: The June 27, 2018 options are being rescinded and a new option is being granted in order to: (i) impose a shareholder-approval requirement for the new option grant, and (ii) remove the cash settlement feature and associated liability from the June 27, 2018 grant. F3 · derivative.exercise_date: Subject to stockholder approval of the option grant, the option will vest and be exercisable with respect to: (i) 25% of the underlying shares as of the grant date (January 13, 2019), (ii) 50% of the underlying shares over a two-year period (vesting ratably quarterly) from June 27, 2018, and (iii) 25% of the underlying shares upon achievement of certain milestones. If the option grant is not approved by stockholders, then the option will not be exercisable. Read SEC document |
| January 13, 2019 Filed Jan 15, 2019 16:10 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,300,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001615774-19-000645 · s115379_form4.xml · derivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,300,000 shares Expires 2028-06-27 F1 · kind: The June 27, 2018 options are being rescinded and a new option is being granted in order to: (i) impose a shareholder-approval requirement for the new option grant, and (ii) remove the cash settlement feature and associated liability from the June 27, 2018 grant. F2 · derivative.exercise_date: Twenty-five percent of the options were vested as of the grant date (June 27, 2018), 50% of the options will vest quarterly over two years from the grant date, and the remaining 25% will vest upon achievement of certain milestones. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 16:03 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 2,300,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001615774-18-005997 · s111131_form4.xml · derivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300,000 Underlying: Common Stock · 2,300,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: Twenty-five percent of the options have vested as of the grant date, 50% of the options will vest quarterly over two years, and the remaining 25% will vest upon achievement of certain milestones. Read SEC document |
| May 30, 2018 Filed May 31, 2018 15:26 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | PurchaseWarrants · Derivative | 2,272 | $1,000.00 Strike: $4.05 | $2,272,000.00 |
DisclosureSEC source: 0001615774-18-004657 · s110546_form4.xml · derivative · entry 2 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,272 Underlying: Common Stock · 2,272 shares Expires 2022-05-30 F4 · price: Shares of Series B Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series B Convertible Preferred Stock and 284 Warrants. F5 · ownership.nature: Securities are owned by Ensisheim Partners, LLC ("Ensisheim"). Shu-Chih Chen, Ph.D. and Steven C. Quay, M.D., Ph.D., share voting and investment power over the securities held by Ensisheim. Ensisheim is solely owned and controlled by Drs. Chen and Quay, and, as a result, Drs. Chen and Quay are deemed to be beneficial owners of the shares held by this entity. Read SEC document |
| May 30, 2018 Filed May 31, 2018 15:26 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | PurchaseSeries B Convertible Preferred Stock · Derivative | 8 | $1,000.00 Strike: $3.52 | $8,000.00 |
DisclosureSEC source: 0001615774-18-004657 · s110546_form4.xml · derivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8 Underlying: Common Stock · 2,273 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock is convertible into the number of shares of Common Stock equal to the stated value of $1,000 divided by $3.52. F4 · price: Shares of Series B Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series B Convertible Preferred Stock and 284 Warrants. F2 · derivative.expiration_date: Shares of Series B Convertible Preferred Stock do not expire. F3 · derivative.underlying_shares: No fractional shares will be issued upon conversion. At its election, the Company will either issue a cash adjustment or round up to the next whole share. The number reflected here assumes rounding up to the next whole share. F5 · ownership.nature: Securities are owned by Ensisheim Partners, LLC ("Ensisheim"). Shu-Chih Chen, Ph.D. and Steven C. Quay, M.D., Ph.D., share voting and investment power over the securities held by Ensisheim. Ensisheim is solely owned and controlled by Drs. Chen and Quay, and, as a result, Drs. Chen and Quay are deemed to be beneficial owners of the shares held by this entity. Read SEC document |
| May 24, 2017 Filed May 26, 2017 13:48 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 575,893 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001615774-17-002743 · s106363_form4.xml · derivative · entry 1 QUAY STEVEN C · CIK 0001008227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,785 Underlying: Common Stock · 575,893 shares Expires 2027-05-24 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 48 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.